Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES2B-C001 With or Without Adjuvant in HER2-expressing Metastatic Breast Cancer
NCT06746688Phase 1Active, not recruiting
- Sponsor
- ExpreS2ion Biotechnologies
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ES2B-C001 in breast cancer (3 cohorts), sponsored by ExpreS2ion Biotechnologies. Primary endpoints: Maximum Tolerated Dose at 18 weeks and Safety and Tolerability at 18 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
ES2B-C001
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06746688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746688.